Latest From Neurotune AG
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.
As blockbuster pipelines dwindle, some large manufacturers see building portfolios of drugs for narrow, related clusters of indications as significant market opportunities. Companies such as GSK, Genzyme, Novartis and Pfizer are finding success with assets that truly address an unmet need and have the potential to be reimbursed at a premium price. However, in many cases, the development and commercialization of narrow-indication drugs are not easy tasks.
The Swiss healthcare venture capital firm, BioMedPartners, has recruited Dr Andreas Schulze as a partner, and promoted Patrick Burgermeister to principal. Dr Schulze was previously CEO of the biotech company, Neurotune, and before that headed the biotech team at the German venture capital firm, DEWB. Mr Burgermeister joined BioMedPartners in 2006 from Novartis, where he was a senior portfolio manager.
- Large Molecule
- In Vitro Diagnostics
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Neurotune AG
- Senior Management
Armin W Mäder, PhD, CEO & CFO
Jan W Vrijbloed, PhD, CSO
Bruno Oesch, PhD, Head, Bus. Dev. & Licensing
- Contact Info
Phone: 44 200 21 95
Wagistrasse 27 a
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.